How I treat sickle cell disease with hematopoietic cell transplantation | Blood | American Society of Hematology
You do not currently have access to this content.
Related Articles
ATM germ line pathogenic variants affect outcomes in children with ataxia-telangiectasia and hematological malignancies
Key PointsThe major cause of death in patients with ataxia-telangiectasia and hematological malignancies is treatment-related toxicity.The germ line ATM pa
Immune modulation permits tolerance and engraftment in a murine model of late-gestation transplantation
Key PointsTransient TCD extends the window of opportunity for donor–specific central tolerance induction in mice.Transient TCD allows for allogeneic engraf
Molecular and clinical presentation of UBA1-mutated myelodysplastic syndromes
Key PointsUBA1 mutations were identified in 1% of patients with MDS and 7% of patients lacking myeloid mutations or established disease classification.Infl
Typhoidal cells: unraveling the diagnostic conundrum in brucellosis instead
A 52-year-old woman was admitted for unexplained thrombocytopenia with a 1-month history of nausea and anorexia. Initial blood tests showed leukocytes at 4.66 × 10…
Monocytes in leukapheresis products affect the outcome of CD19–targeted CAR T-cell therapy in patients with lymphoma
Combining circulating absolute monocyte count and a 4-gene monocyte signature at leukapheresis predicts PFS of LBCL receiving CAR T cells.Monocytes depleti
Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia in Adults over 70 years old
The advent of reduced-intensity conditioning regimens, improvements in graft-versus-host disease prophylaxis, and better supportive care have permitted inc
Final outcomes from a phase 2 trial of posoleucel in allogeneic hematopoietic cell transplant recipients
Key PointsAllogeneic hematopoietic cell transplant recipients are at risk of clinically significant viral infections due to lack of T-cell immunity.The mul
Clinical outcomes after idecabtagene vicleucel in older patients with multiple myeloma: a multicenter real-world experience
Key PointsThe safety and efficacy benefits of ide-cel were proportionate in young and older patients despite frailty and geriatric characteristics.Treatmen
Anti-CD37 CAR T cells: another arrow in the quiver
In this issue of Blood, Frigault et al1 describe the first-in-human trial of anti-CD37 chimeric antigen receptor (CAR) T cells in patients with refractory